Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) dated April 7, 2026. The company granted 8,925 restricted stock units to six non-executive employees that vest over four years, with 25% vesting each year.

This action was approved by Rigel's Compensation Committee and issued as inducements for new employees joining the company.

News Market Reaction – RIGL

+5.01%

10 alerts

+5.01% Session close to close

$530.92M Market Cap

1.1x Rel. Volume

In the Apr 7 session, RIGL gained 5.01%, reflecting a notable positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.0% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.0% in the session following this news. A strong positive reaction aligns with the company’s pattern of occasionally sharp moves around routine corporate updates, even when fundamentals are unchanged. These inducement RSUs to six employees represent standard hiring-related equity and do not modify guidance or clinical timelines. Investors watching sustainability would typically monitor upcoming catalysts like earnings or trial data, as purely administrative equity grants can see enthusiasm fade without follow-on fundamental news.

Key Figures

Inducement RSUs: 8,925 units Employees granted: 6 employees Vesting period: 4 years +3 more

6 metrics

Inducement RSUs 8,925 units Granted to new non-executive employees under Inducement Plan

Employees granted 6 employees Non-executive hires receiving inducement RSU awards

Vesting period 4 years RSUs vest over four years as part of employment inducement

Annual vesting rate 25% per year One-quarter of each RSU grant vests annually

Founding year 1996 Year Rigel Pharmaceuticals, Inc. was founded

Listing rule 5635(c)(4) NASDAQ Listing Rule governing inducement equity grants

Historical Context

5 past events · Latest: Mar 31 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 31	Clinical data update	Positive	+5.1%	Final Phase 1/2 ARROW data for GAVRETO in RET+ NSCLC published.
Mar 03	Earnings results	Positive	-10.3%	Strong Q4 and 2025 revenue, net income, and 2026 guidance released.
Feb 24	Earnings call notice	Neutral	+0.7%	Announcement of schedule for Q4 and full-year 2025 results call.
Feb 03	Board appointment	Positive	+0.5%	Appointment of Michael P. Miller to the Board of Directors.
Jan 15	Clinical trial start	Positive	-0.8%	First patient enrolled in Phase 1b/2 REZLIDHIA AML combination trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has drawn mixed reactions: positive clinical and management updates often aligned with modest gains, while strong earnings and certain clinical updates saw negative follow-through.

Recent Company History

Over recent months, Rigel has reported key clinical data, strong 2025 financial results, board refreshment, and advancement of its AML program. The stock rose 5.13% on final ARROW data for GAVRETO but fell 10.27% on a robust earnings update, showing occasional divergence between fundamentals and price. Management and pipeline-related news around early 2026 tended to produce smaller, mixed reactions, framing today’s inducement RSU grants as a routine HR and compensation event within an active strategic period.

Key Terms

restricted stock units, inducement plan, nasdaq listing rule 5635(c)(4)

3 terms

restricted stock units financial

"Specifically, Rigel granted 8,925 restricted stock units to six non-executive employees..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement plan financial

"granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by..."

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

nasdaq listing rule 5635(c)(4) regulatory

"with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 8,925 restricted stock units to six non-executive employees vesting over four years with 25% of the grant vesting each year.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & Media
Rigel Pharmaceuticals, Inc. 
650.624.1232
ir@rigel.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302735168.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

What inducement grants did Rigel (RIGL) announce on April 7, 2026?

Rigel granted 8,925 restricted stock units to six non-executive employees as inducement awards. According to the company, the awards were approved by the Compensation Committee and issued under Nasdaq Listing Rule 5635(c)(4) for new hires.

How do the Rigel (RIGL) restricted stock units vest and over what timeframe?

The restricted stock units vest over four years with 25% of each grant vesting annually. According to the company, the schedule is a standard four-year, annual-vesting plan for the six non-executive employees.

Who received the inducement awards from Rigel (RIGL) and were executives included?

The awards went to six non-executive employees; no executive recipients were reported. According to the company, the grants were specifically issued as inducements for employees entering into employment with Rigel.

Under which Nasdaq rule did Rigel (RIGL) grant the inducement restricted stock units?

Rigel issued the awards under Nasdaq Listing Rule 5635(c)(4), which permits inducement grants for new employees. According to the company, the Compensation Committee approved the awards consistent with that rule.

Will the Rigel (RIGL) inducement grants likely affect current shareholders immediately?

The announcement reports 8,925 RSUs granted, a small, specified grant to six hires; immediate shareholder impact was not quantified. According to the company, the awards were granted as inducements and no dilution percentage was provided.